Skip to content Skip to sidebar Skip to footer

Technology

ASX Dividend Stocks
Top 3 Small Cap ASX Stocks For 2026 (Full Analysis)
Small cap equities have underperformed broader market indices, and this has led some investors to revisit the asset class in search of better value relative to increasingly expensive large cap stocks. The Russell 2000 has lagged meaningfully, as capital has been concentrated in a narrow group of mega cap winners that continue to dominate index…
RocketBoots
Is RocketBoots (ASX:ROC) a buy after a 200% surge?
RocketBoots Secures A$9M ARR Deal and A$7M Raise to Fuel Global Growth RocketBoots (ASX:ROC) has emerged as a standout small cap on the ASX, capturing investor attention following the announcement of a A$9 million annual recurring revenue contract with a global tier one retailer. More recently, the company raised A$7 million through a placement to…
Sprintex
Sprintex (ASX:SIX) Soars 46% on A$27M Contract
Sprintex’s A$27M Contract Moves It from Concept to Commercial Execution Sprintex (ASX:SIX) surged 46% today after announcing it had secured approximately A$27 million in contracted orders, a development that meaningfully changes the investment narrative. The agreement with MW Techniek covers 500 ZLD UP compressor systems and 500 integrated PLC control systems, with deliveries scheduled over…
ASX Predictions for 2026
Our 5 ASX Predictions for 2026!
This article outlines 5 ASX Predictions for 2026 that Stocks Down Under puts its neck on the line to assert will happen. It has become an annual tradition of ours, and some of these calls we get right, others we don't. Arguably our boldest call in suggesting ANZ would be the best performing big 4…
invion
Invion (ASX:IVX) Surges 20% on Non-Dilutive Funding for Cancer Program
Invion Secures Non-Dilutive Backing to Advance Cancer Therapy Invion (ASX:IVX) saw a sharp rerating today, with the share price rising 20% following the announcement of potential non-dilutive funding that meaningfully changes the near-term risk profile of the business. Rather than issuing new shares to advance its oesophageal cancer program, Hanlim Pharm will fund the required preclinical…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here